Influenza epidemics observed in primary care from 1984 to 2017 in France: A decrease in epidemic size over time.


Journal

Influenza and other respiratory viruses
ISSN: 1750-2659
Titre abrégé: Influenza Other Respir Viruses
Pays: England
ID NLM: 101304007

Informations de publication

Date de publication:
03 2019
Historique:
received: 13 03 2018
revised: 07 09 2018
accepted: 06 11 2018
pubmed: 15 11 2018
medline: 30 11 2019
entrez: 15 11 2018
Statut: ppublish

Résumé

Epidemiological analysis of past influenza epidemics remains essential to understand the evolution of the disease and optimize control and prevention strategies. Here, we aimed to use data collected by a primary care surveillance system over the last three decades to study trends in influenza epidemics and describe epidemic profiles according to circulating influenza viruses. Influenza-like illness (ILI) weekly incidences were estimated using cases reported by general practitioners participating in the French Sentinelles network, between 1984 and 2017. Influenza epidemics were detected by applying a periodic regression to this time series. Epidemic (co-)dominant influenza virus (sub)types were determined using French virology data. During the study period, 297 607 ILI cases were reported allowing the detection of 33 influenza epidemics. On average, seasonal epidemics lasted 9 weeks and affected 4.1% of the population (95% CI 3.5; 4.7). Mean age of cases was 29 years. Epidemic size decreased over time by -66 cases per 100 000 population per season on average (95% CI -132; -0.2, P value = 0.049) and epidemic height decreased by -15 cases per 100 000 (95% CI -28; -2, P value = 0.022). Epidemic duration appeared stable over time. Epidemics were mostly dominated by A(H3N2) (n = 17, 52%), associated with larger epidemic size, higher epidemic peak and older age of cases. The declining trend in influenza epidemic size and height over the last 33 years might be related to several factors like increased vaccine coverage, hygiene improvements or changing in influenza viruses. However, further researches are needed to assess the impact of potential contributing factors to adapt influenza plans.

Sections du résumé

BACKGROUND
Epidemiological analysis of past influenza epidemics remains essential to understand the evolution of the disease and optimize control and prevention strategies. Here, we aimed to use data collected by a primary care surveillance system over the last three decades to study trends in influenza epidemics and describe epidemic profiles according to circulating influenza viruses.
METHODS
Influenza-like illness (ILI) weekly incidences were estimated using cases reported by general practitioners participating in the French Sentinelles network, between 1984 and 2017. Influenza epidemics were detected by applying a periodic regression to this time series. Epidemic (co-)dominant influenza virus (sub)types were determined using French virology data.
RESULTS
During the study period, 297 607 ILI cases were reported allowing the detection of 33 influenza epidemics. On average, seasonal epidemics lasted 9 weeks and affected 4.1% of the population (95% CI 3.5; 4.7). Mean age of cases was 29 years. Epidemic size decreased over time by -66 cases per 100 000 population per season on average (95% CI -132; -0.2, P value = 0.049) and epidemic height decreased by -15 cases per 100 000 (95% CI -28; -2, P value = 0.022). Epidemic duration appeared stable over time. Epidemics were mostly dominated by A(H3N2) (n = 17, 52%), associated with larger epidemic size, higher epidemic peak and older age of cases.
CONCLUSIONS
The declining trend in influenza epidemic size and height over the last 33 years might be related to several factors like increased vaccine coverage, hygiene improvements or changing in influenza viruses. However, further researches are needed to assess the impact of potential contributing factors to adapt influenza plans.

Identifiants

pubmed: 30428158
doi: 10.1111/irv.12620
pmc: PMC6379635
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

148-157

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2018 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.

Références

Popul Health Metr. 2014 Jul 26;12:19
pubmed: 25435814
Arch Intern Med. 2002 Sep 9;162(16):1842-8
pubmed: 12196082
PLoS One. 2013 Jun 05;8(6):e65919
pubmed: 23755294
MMWR Recomm Rep. 2013 Sep 20;62(RR-07):1-43
pubmed: 24048214
BMC Public Health. 2012 Nov 05;12:947
pubmed: 23127166
Eur J Epidemiol. 2003;18(8):751-4
pubmed: 12974549
PLoS One. 2007 Dec 12;2(12):e1296
pubmed: 18074020
Influenza Other Respir Viruses. 2019 Mar;13(2):148-157
pubmed: 30428158
Influenza Other Respir Viruses. 2008 Jul;2(4):139-45
pubmed: 19453466
PLoS Med. 2008 Mar 25;5(3):e74
pubmed: 18366252
JAMA. 2003 Jan 8;289(2):179-86
pubmed: 12517228
Euro Surveill. 2006;11(5):111-8
pubmed: 16757850
Nature. 2003 Mar 27;422(6930):428-33
pubmed: 12660783
PLoS Pathog. 2014 Jun 26;10(6):e1004206
pubmed: 24968312
Clin Infect Dis. 1999 Feb;28(2):283-90
pubmed: 10064245
Am J Public Health. 1991 Jan;81(1):97-9
pubmed: 1983924
Proc Natl Acad Sci U S A. 2012 Dec 26;109(52):21474-9
pubmed: 23236176
Euro Surveill. 2018 Jun;23(25):
pubmed: 29945696
Science. 2006 Apr 21;312(5772):447-51
pubmed: 16574822
BMC Infect Dis. 2010 Jun 09;10:162
pubmed: 20534113
Stud Health Technol Inform. 2010;160(Pt 1):442-6
pubmed: 20841725
Epidemiol Infect. 2009 Apr;137(4):473-9
pubmed: 18789176
Am J Public Health. 1997 Dec;87(12):1944-50
pubmed: 9431281
PLoS One. 2009 Aug 31;4(8):e6832
pubmed: 19718262
Nature. 2008 May 29;453(7195):615-9
pubmed: 18418375
Infect Control Hosp Epidemiol. 2010 May;31(5):535-7
pubmed: 20334548
Epidemiol Infect. 2018 Jan;146(2):168-176
pubmed: 29208062
Am J Public Health. 1986 Nov;76(11):1289-92
pubmed: 3766824
Int J Epidemiol. 2006 Oct;35(5):1314-21
pubmed: 16926216
J Clin Virol. 2017 Oct;95:1-4
pubmed: 28818690
Eur J Epidemiol. 1999 May;15(5):467-73
pubmed: 10442473
BMC Infect Dis. 2015 Aug 21;15:357
pubmed: 26289794
Lancet. 2017 Aug 12;390(10095):697-708
pubmed: 28302313
Euro Surveill. 2006;11(10):249-50
pubmed: 17130657
Clin Microbiol Infect. 2018 Apr;24(4):431.e5-431.e12
pubmed: 28899840
PLoS One. 2012;7(9):e45051
pubmed: 23028756
Rev Infirm. 2005 Nov;(115):33-6
pubmed: 16375246
Stat Methods Med Res. 2006 Oct;15(5):413-21
pubmed: 17089946
Pharmacoeconomics. 1996;9 Suppl 3:62-6
pubmed: 10160489

Auteurs

Cécile Souty (C)

Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Paris, France.

Philippe Amoros (P)

Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Paris, France.

Alessandra Falchi (A)

EA7310, Laboratoire de Virologie, Université de Corse-Inserm, Corte, France.

Lisandru Capai (L)

Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Paris, France.
EA7310, Laboratoire de Virologie, Université de Corse-Inserm, Corte, France.

Isabelle Bonmarin (I)

Department of Infectious Diseases, Santé publique France, Saint-Maurice, France.

Sylvie van der Werf (S)

Institut Pasteur, Unité de Génétique Moléculaire des Virus à ARN, Paris, France.
Institut Pasteur, Centre Coordonnateur du Centre National de Référence des virus des infections respiratoires (dont la grippe), Paris, France.
UMR CNRS 3569, Paris, France.
Université Paris Diderot, Sorbonne Paris Cité, Unité de Génétique Moléculaire des Virus à ARN, Paris, France.

Shirley Masse (S)

Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Paris, France.
EA7310, Laboratoire de Virologie, Université de Corse-Inserm, Corte, France.

Clément Turbelin (C)

Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Paris, France.

Louise Rossignol (L)

Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Paris, France.

Ana-Maria Vilcu (AM)

Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Paris, France.

Daniel Lévy-Bruhl (D)

Department of Infectious Diseases, Santé publique France, Saint-Maurice, France.

Bruno Lina (B)

Laboratoire de Virologie, Hospices Civils de Lyon, Institut des Agents Infectieux (IAI), Centre National de Référence des virus respiratoires (dont la grippe), Centre de Biologie et de Pathologie Nord, Groupement Hospitalier Nord, Lyon, France.
Université de Lyon, Virpath, CIRI, INSERM U1111, CNRS UMR5308, ENS Lyon, Université Claude Bernard Lyon 1, Lyon, France.

Laëtitia Minodier (L)

EA7310, Laboratoire de Virologie, Université de Corse-Inserm, Corte, France.

Yves Dorléans (Y)

Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Paris, France.

Caroline Guerrisi (C)

Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Paris, France.

Thomas Hanslik (T)

Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Paris, France.
Université de Versailles Saint-Quentin-en-Yvelines, UVSQ, UFR de Médecine, Versailles, France.
Service de Médecine Interne, Hôpital Ambroise Paré, Assistance Publique - Hôpitaux de Paris, APHP, Boulogne Billancourt, France.

Thierry Blanchon (T)

Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH